Australia CBD Products Market Size, Share, Trends & Analysis Report 2025-2033

Market Overview

The Australia CBD products market was valued at USD 0.22 Billion in 2024 and is projected to reach USD 0.50 Billion by 2033. The market is expected to grow steadily during the forecast period of 2025-2033, driven by rising demand for natural wellness solutions. With a CAGR of 9.61%, growth is fueled by product innovation, regulatory easing, and increasing consumer awareness favoring holistic health alternatives. These trends position Australia as a significant player in the expanding global CBD landscape.

How AI is Reshaping the Future of the Australia CBD Products Market:

• AI-powered product innovation accelerates the development of tailored CBD formulations, enhancing purity, potency, and bioavailability, exemplified by breakthroughs such as Tilray Medical’s EU-GMP-accredited Redecan cannabis products.
• Machine learning algorithms analyze consumer preferences and wellness needs to optimize marketing strategies across pharmacy and telehealth platforms, expanding over-the-counter (OTC) CBD access.
• AI-driven supply chain management facilitates traceability and quality control throughout vertically integrated hemp production in regions like Tasmania and Western Australia, ensuring pharmaceutical-grade consistency.
• Natural language processing and chatbots improve educational outreach, addressing public perception and knowledge gaps about CBD versus THC, thus building confidence among conservative and rural consumers.
• Predictive analytics support regulatory submissions by modeling clinical evidence requirements for Therapeutic Goods Administration (TGA) approval, streamlining product launches.
• AI-enabled export optimization leverages Australia’s preferential trade agreements and proximity to Asia-Pacific markets, enhancing efficient distribution of "Made in Australia" CBD products to emerging countries like Japan and Thailand.

Grab a sample PDF of this report: https://www.imarcgroup.com/australia-cbd-products-market/requestsample

Market Growth Factors

The rising legal acceptance and regulatory development in Australia significantly drive the CBD products market. The Therapeutic Goods Administration (TGA) has gradually eased restrictions on low-dose cannabidiol, making certain CBD products available over the counter. This evidence-based regulatory approach guarantees high product quality and efficacy standards, which fosters consumer trust. The legal normalization of medicinal cannabis, notably in New South Wales and Victoria, further encourages adoption for anxiety, sleep, and chronic pain relief. Local and international companies have responded by expanding their product offerings to the market, contributing to its robust growth.

Unique agricultural capacity and domestic production serve as another key market driver. Australia’s favorable climatic and geographic conditions enable high-quality hemp cultivation, pivotal for CBD extraction. Areas like Tasmania and parts of Western Australia have expanded cultivation efforts, supporting both domestic and export supply chains. The vertical integration of this supply chain reduces import dependence and production costs while enabling superior traceability and quality control. Such agricultural competence underpins the availability of diverse CBD applications, including skincare and wellness supplements, fortifying Australia's position as a major hemp-sourced CBD provider.

Increasing health consciousness and shifting consumer attitudes also promote market development. Australian consumers in major cities embrace wellness cultures focused on natural and plant-based treatments. CBD’s integration into mental health routines, fitness recovery, and proactive care aligns with lifestyle trends. Local producers have innovated products tailored to Australian lifestyles, such as topical balms for surf-related joint pain and tinctures for outdoor endurance. The declining stigma around cannabis use, bolstered by education drives and medical advocacy, further accelerates demand, stimulating continuous innovation and investment in the local CBD market.

Market Segmentation

Source Insights:

• Hemp
• Marijuana

Distribution Channel Insights:

• B2B
• B2C

Application Insights:

• Pharmaceutical
• Wellness

Regional Insights:

• Australian Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

Key Players

• Tilray Medical
• FoliuMed
• Charlotte's Web
• Avecho Biotechnology
• Sandoz

Recent Developments & News

• April 2025: Tilray launched its first range of cannabis-infused medical edibles in Australia under the Good Supply brand. The sugar-free, vegan-friendly pastilles are available in THC10, THC10 CBD10, and CBD20 variants, expanding treatment options for medical cannabis patients and marking significant international expansion.
• March 2025: Avecho Biotechnology partnered with Sandoz via a 10-year exclusive license and development agreement to commercialize Avecho’s CBD capsule for insomnia in Australia. The agreement includes milestone payments and aims for Therapeutic Goods Administration (TGA) approval, enhancing availability of therapeutics.

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask an Analyst for Your Customized Sample Report: https://www.imarcgroup.com/request?type=report&id=33027&flag=C

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St., Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201-971-6302